About Teijin Pharma
As the core of the Teijin Group’s healthcare business, Teijin Pharma maximizes Teijin solutions in applications throughout the healthcare cycle. From disease prevention and healthy living, to treatment, rehabilitation and nursing care, we use our access to the full breadth of Teijin expertise to synergize pharmaceuticals and medical devices that are innovative in their fields. We define our four core priority fields as bone and joint, rehabilitation and neurology, respiratory, and cardiovascular and metabolic. Driven by our philosophy to improve Quality of Life, we support both patients and medical professionals with expert knowledge and coordination behind every solution.
Community-based, integrated care is the ideal environment for patients to receive healthcare at home. We designed a patient information sharing system, VitalLink®, that facilitates this ideal environment. The system keeps patients’ medical teams updated on their status and condition in real time, including doctors, nurses and certified care workers. There are also 100 Teijin support offices and home visit nursing stations Japan-wide. Our in-house medical experts work together with experienced sales staff and home care professionals to support comprehensive care.
We launched Onealfa®, an active vitamin D₃ drug, in 1981. Developed in-house at Teijin, it was pioneering in the treatment of osteoporosis. We followed this with Bonalon®, another osteoporosis drug, acquired through a cross-licensing agreement. And we continue adding to our bone and joint line-up to help patients extend their time with healthy mobility as populations age, introducing LOQOA® tape, a transdermal anti-inflammatory analgesic patch formulation for osteoarthritis, and SAFHS®, a sonic accelerated fracture healing system used in home healthcare.
Bonalon® is a trademark of Merck Sharp & Dohme Corp.
LOQOA® is a trademark of Taisho Pharmaceutical Co., Ltd.
The freedom to move yourself is an essential part of protecting Quality of Life. We are approaching motor skills and mobility through neurology, advancing the potential for recovery from damage to the central nervous system caused by stroke, injury or trauma. WalkAide®, a neuromuscular electrical stimulation device for walking support, and ReoGo®-J, a robot for rehabilitating paralyzed upper limbs, are two devices we currently carry for this purpose. We are also exploring medical devices for treating depression, including the NeuroStar® Transcranial Magnetic Stimulation.
ReoGo® is a trademark of Motorika Medical Ltd.
Teijin created Japan’s first membrane-type oxygen concentrator, and as a leader in the field, we have expert knowledge and a highly effective team structure in place to support patients of home oxygen therapy (HOT). Our customer center is open 24 hours a day, 365 days a year. When patients travel, we can arrange to have oxygen cylinders delivered to their destination and in the event of a disruptive disaster, such as an earthquake or tsunami, our system automatically collates data on affected patients, enabling us to coordinate emergency equipment.
Correctly predicting the steady increase in lifestyle-related diseases, we put significant effort into R&D in this field. These efforts bore fruit with the development of Febuxostat®, a treatment for hyperuricemia and gout. Febuxostat® won the Pharmaceutical Society of Japan Award for Drug Research and Development and is now sold in 78 regions worldwide (as of June 2020).